JP2010536761A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536761A5
JP2010536761A5 JP2010521050A JP2010521050A JP2010536761A5 JP 2010536761 A5 JP2010536761 A5 JP 2010536761A5 JP 2010521050 A JP2010521050 A JP 2010521050A JP 2010521050 A JP2010521050 A JP 2010521050A JP 2010536761 A5 JP2010536761 A5 JP 2010536761A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
stereoisomer
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536761A (ja
JP5645663B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/009793 external-priority patent/WO2009023272A1/en
Publication of JP2010536761A publication Critical patent/JP2010536761A/ja
Publication of JP2010536761A5 publication Critical patent/JP2010536761A5/ja
Application granted granted Critical
Publication of JP5645663B2 publication Critical patent/JP5645663B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521050A 2007-08-15 2008-08-15 ネクロトーシスのヘテロ環式抑制剤 Active JP5645663B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95596607P 2007-08-15 2007-08-15
US60/955,966 2007-08-15
US3817508P 2008-03-20 2008-03-20
US61/038,175 2008-03-20
PCT/US2008/009793 WO2009023272A1 (en) 2007-08-15 2008-08-15 Heterocyclic inhibitors of necroptosis

Publications (3)

Publication Number Publication Date
JP2010536761A JP2010536761A (ja) 2010-12-02
JP2010536761A5 true JP2010536761A5 (enExample) 2011-09-29
JP5645663B2 JP5645663B2 (ja) 2014-12-24

Family

ID=40351022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521050A Active JP5645663B2 (ja) 2007-08-15 2008-08-15 ネクロトーシスのヘテロ環式抑制剤

Country Status (5)

Country Link
US (5) US20090099242A1 (enExample)
EP (2) EP2192838A4 (enExample)
JP (1) JP5645663B2 (enExample)
CA (1) CA2696349A1 (enExample)
WO (1) WO2009023272A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2384753B1 (en) * 2003-08-29 2016-01-06 The Brigham and Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
EP1968583A4 (en) * 2005-12-20 2010-09-15 Harvard College COMPOUNDS, SCREENING AND TREATMENT PROCEDURES
JP2012513481A (ja) 2008-12-23 2012-06-14 プレジデント アンド フェロウズ オブ ハーバード カレッジ ネクロトーシスの小分子阻害剤
WO2011133964A2 (en) 2010-04-23 2011-10-27 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
EP2580201B1 (en) 2010-06-11 2017-08-02 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
CA2802294C (en) 2010-06-11 2016-05-10 Rhodes Technologies Process for n-dealkylation of tertiary amines
WO2012061045A2 (en) 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
US9643977B2 (en) 2011-03-11 2017-05-09 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
EP2773341A2 (en) 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
CN103535358B (zh) * 2013-10-18 2015-04-15 孙家隆 一组邻位取代苯甲酰化合物的杀菌剂用途
SG11201704764PA (en) 2014-12-11 2017-07-28 Harvard College Inhibitors of cellular necrosis and related methods
EP3224245B1 (en) 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
WO2016101885A1 (en) 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
MD3788045T2 (ro) 2018-05-03 2023-09-30 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
HRP20231381T1 (hr) 2018-05-03 2024-03-01 Rigel Pharmaceuticals, Inc. Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
CN113272272B (zh) 2018-11-20 2023-04-07 圣瑞诺有限公司 Rip1抑制剂
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
CA3149926A1 (en) 2019-09-06 2021-03-11 Yan Chen Rip1 inhibitory compounds and methods for making and using the same
JP7493586B2 (ja) 2019-09-06 2024-05-31 ライジェル ファーマシューティカルズ, インコーポレイテッド Rip1阻害化合物ならびにそれを作製および使用するための方法
SI4055021T1 (sl) 2019-11-07 2026-02-27 Rigel Pharmaceuticals, Inc. Heterociklične spojine, ki inhibirajo rip1
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
JP7774579B2 (ja) 2020-05-20 2025-11-21 シロナックス リミテッド. ピペラジン複素環アミド尿素類を含む受容体共役タンパク質1阻害剤
IL298188A (en) 2020-05-20 2023-01-01 Sironax Ltd Circular structures of piperazine
TWI840311B (zh) 2020-07-01 2024-04-21 美商雷傑製藥公司 Rip1k抑制劑
CA3198930A1 (en) * 2020-11-19 2022-05-27 Acousia Therapeutics Gmbh Non-aqueous gel composition
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
IL308348A (en) 2021-05-20 2024-01-01 Sironax Ltd RIP1 modulators including cyclic ureas aztidine, their preparation and uses

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2728523C2 (de) * 1977-06-23 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 4-Methyl-1,2,3-thiadiazol-5-carbonsäure-(cyclohexylmethyl)-amid, Mittel mit herbizider und wachstumsregulatorischer Wirkung enthaltend diese Verbindung sowie Verfahren zu seiner Herstellung
US4356787A (en) 1977-12-30 1982-11-02 Harley Richard C Float construction
EP0930305B1 (en) 1996-09-30 2003-05-14 Nihon Nohyaku Co., Ltd. 1,2,3-thiadiazole derivatives and salts thereof, disease controlling agents for agricultural and horticultural use, and method for the use thereof
JPH10152482A (ja) * 1996-09-30 1998-06-09 Nippon Nohyaku Co Ltd 1,2,3−チアジアゾール誘導体又はその塩類及び農園芸用病害防除剤ならびにその使用方法
DE69903992T2 (de) * 1998-04-15 2003-08-21 Pfizer Products Inc., Groton Heterocyclische Carboxamide
ATE238661T1 (de) * 1998-07-30 2003-05-15 Nihon Nohyaku Co Ltd Fungizide zusammensetzung enthaltend ein 1,2,3- thiadiazolderivat sowie deren verwendung
JP2000103710A (ja) * 1998-07-30 2000-04-11 Nippon Nohyaku Co Ltd 殺菌剤組成物及びその使用方法
US6756394B1 (en) * 1999-10-15 2004-06-29 President And Fellow Of Harvard College Small molecule inhibitors of necrosis
US6420400B1 (en) * 2000-04-07 2002-07-16 Kinetek Pharmaceuticals, Inc. Antiproliferative 1,2,3-thiadiazole compounds
EP1386913B1 (en) * 2001-04-19 2008-07-16 Dainippon Sumitomo Pharma Co., Ltd. Pyrrole derivative
DE10132686A1 (de) * 2001-07-05 2003-01-16 Boehringer Ingelheim Pharma Heteroarylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2003030937A1 (en) * 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
ATE375980T1 (de) 2002-02-12 2007-11-15 Smithkline Beecham Corp Nicotinamide und deren verwendung als p38 inhibitoren
DE10261131A1 (de) * 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
WO2005000821A1 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Tachykinin receptor antagonists
EP2384753B1 (en) 2003-08-29 2016-01-06 The Brigham and Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
US7462612B2 (en) * 2004-03-26 2008-12-09 Vertex Pharmaceuticals Incorporated Pyridine inhibitors of ERK2 and uses thereof
CA2573426C (en) * 2004-07-30 2015-11-17 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
PL1848435T3 (pl) * 2005-01-25 2016-08-31 Synta Pharmaceuticals Corp Związki przeciwko zapaleniom i zastosowania związane z odpornością
ZA200707353B (en) * 2005-02-24 2009-03-25 Nihon Nohyaku Co Ltd 4-cyclopropyl-1,2,3-thiadiazole compound, agrohorticultural plant disease controlling agent and method of using the same
EP1968583A4 (en) 2005-12-20 2010-09-15 Harvard College COMPOUNDS, SCREENING AND TREATMENT PROCEDURES
JP2007186435A (ja) * 2006-01-12 2007-07-26 Astellas Pharma Inc ニコチンアミド誘導体
US8455658B2 (en) 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
US20070254926A1 (en) * 2006-01-31 2007-11-01 Jun Jiang Pyridylphenyl compounds for inflammation and immune-related uses
AU2007227210A1 (en) * 2006-03-20 2007-09-27 Synta Pharmaceuticals Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
AU2007230911A1 (en) * 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
US20100087453A1 (en) 2006-10-10 2010-04-08 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
EP1995241B1 (en) * 2007-03-23 2010-03-17 ICAgen, Inc. Inhibitors of ion channels
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
JP2012513481A (ja) 2008-12-23 2012-06-14 プレジデント アンド フェロウズ オブ ハーバード カレッジ ネクロトーシスの小分子阻害剤

Similar Documents

Publication Publication Date Title
JP2010536761A5 (enExample)
JP4611444B2 (ja) ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
JP5989660B2 (ja) 置換1−ベンジルシクロアルキルカルボン酸およびその使用
WO2016081649A1 (en) Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
EP3349761A1 (en) Hepatitis b core protein modulators
JP2010522709A5 (enExample)
JP2008513496A5 (enExample)
WO2008054454A2 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
JP2016512531A5 (enExample)
JP2006528617A5 (enExample)
JP2010504351A5 (enExample)
JP2015508092A5 (enExample)
RU2011124150A (ru) Нафтилуксусные кислоты
JP2010522711A5 (enExample)
JP2007527913A5 (enExample)
JP2010522710A5 (enExample)
JP2025003530A (ja) アルドースレダクターゼの阻害剤
JP2010513489A5 (enExample)
JP6518692B2 (ja) 多環式herg活性化剤
JP2009536967A5 (enExample)
WO2008113747A1 (en) Medicaments useful as potassium channel modulators
TWI555528B (zh) 泛醇基二十二碳六烯酸酯及其於治療與預防心血管疾病的用途
CN1225466C (zh) Ⅰ型钠-氢交换剂(nhe-1)抑制剂
CN1921855A (zh) 用于选择性增强心房收缩力以及治疗心功能不全的kv1.5-阻滞剂
AU2020216498A1 (en) Bicyclic pyridine compositions and methods of using the same for cancer therapy